Skip to main content

Table 3 The radiosensitivity level of breast cancer patients, BRCA1/2 mutation carriers and breast cancer patients with radiotherapy complication, using comet assay

From: Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays

Reference

Marker

Sample size

Cell type

Radiation dose

Result

Breast cancer

 Lou et al. 2008 [133]

Comet assay

1. BC cases (25)

Lymphocyte

3-Gy

Spontaneous RS

2. Healthy controls (25)

X-rays

Healthy controls ↔ BC cases

RS after radiation

BC cases > Healthy controls

 Shahidi et al. 2007 [157]

Alkaline and Neutral Comet assay

1. BC cases (35)

Lymphocyte

Alkaline

Alkaline & Neutral Comet assay

2. Healthy controls (29)

1 Gy

Spontaneous RS

γ-rays

BC cases > Healthy controls

Neutral

Alkaline & Neutral Comet assay

2 Gy

Initial RS

Alkaline & Neutral Comet assay

γ-rays

BC cases ↔ Healthy controls

 Djuzenova et al. 2006 [12]

Comet assay

1. BC cases (50)

PBMC

5 Gy

Spontaneous RS

2. Healthy controls (16)

X-rays

BC cases ↔ Healthy controls

Initial RS

BC cases ↔ Healthy controls

Residue RS

BC cases ↔ Healthy controls

 Zhang et al. 2006 [156]

Comet assay

1. Malignant breast tumor (14)

PBMC

0.5 Gy

Spontaneous RS

2. Benign breast tumor (18)

γ-rays

Malignant ↔ Benign

Residue RS

Malignant > Benign

BRCA1 mutation

 Kotsopoulos et al. 2007 [13]

Comet assay

1. Healthy BRCA1 mutation carriers (25)

Lymphocyte

2 Gy

Spontaneous RS

2. Non-carrier control (25)

γ-rays

Healthy BRCA1 mutation carriers ↔ Non-carrier controls

RS after radiation

Healthy BRCA1 mutation carriers ↔ Non-carrier controls

 Trenz et al (2002) [141]

Comet assay

1. Healthy BRCA1 mutation carriers (5)

Lymphocyte

2 Gy

RS after radiation

2. Healthy BRCA2 mutation carriers (3)

γ-rays

BRCA1 mutation carriers ↔ BRCA2

3. Healthy controls W/O familial history of cancer (6)

mutation carriers

BRCA1/2 mutation carriers ↔ Healthy controls

 Rothfus et al. (2000) [142]

Comet assay

1. Healthy BRCA1 mutation carriers (12)

Lymphocyte

2 Gy

RS after radiation

2. Non-carrier subjects from BRCA1 families (10)

γ-rays

No difference across all groups

3. Healthy controls W/O history of cancer (17)

Radiotherapy complications

 Djuzenova et al. 2006 [12]

Comet assay

1. BC cases with ASR (9)

PBMC

5 Gy

Spontaneous RS

2. BC cases (50)

X-rays

BC with ASR ↔ Healthy controls

3. Healthy controls (16)

BC with ASR ↔ BC cases

RS after radiation

BC with ASR ↔ Healthy controls

BC with ASR ↔ BC cases

 Oppitz et al. 2002 [158]

Comet assay

1. BC cases (32)

Lymphocyte & Fibroblast

Lymphocyte

Lymphocyte

A. Lymphocyte (30)

3Gy

RS after radiation

B. Fibroblast (26)

Fibroblast

Elevated acute reactions > Average acute reactions

5Gy

Fibroblast

Radiosensitivity after radiation

Elevated acute reactions ↔ Average acute reactions

  1. RS radiosensitivity, BC breast cancer, PBMC peripheral blood mononuclear cell, W/O without, Gr gray
  2. ↔: no significant differences at the radiosensitivity level, >: significant higher level of radiosensitivity